Specification
| Reactivities | Human |
| Target | Her2xHer |
| Approved Therapeutic | Zenocutuzumab |
| Isotype | Human IgG1(K214R/L351K/T366K//K214R/L351D/L368E)-Kappa |
| Property | Antibody |
| Alernative Name | MCLA-128；PB4188,R040517；epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340;receptor tyrosine-protein kinase erbB-3, HER3 |
| Recommended Isotype | |
| Recommended Buffer | PBS, pH 7.4,Contains no stabilizers or preservatives. |
| Formulation Buffer | PBS, pH 7.4,Contains no stabilizers or preservatives |
| Endotoxin | <1EU/mg Determined by LAL gel clotting assay |
| Purity | >90% Determined by SDS-PAGE |
| Sterility | 0.2 μM filtered |
| Expression Host | CHO |
| Purification Method | Protein A |
| Storage | The product need to be stored at the original stock concentration at 4°C.Avoid freeze / thaw cycle. |
| Note | Due to the variability in applications, investigators should consult application references to estimate the appropriate dose or concentration. This dose or concentration can then be further optimized through experimental methods such as dose-response or titration experiments |
Background
QC Data
| Note | Please contact us for QC Data |
| Product Image (Reference Only) |  |